The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.
More Latest News
November 7, 2022
On Monday, November 7, 2022, Governor Ron DeSantis declared a State of Emergency to prepare for Subtropical Storm Nicole. Continue reading
October 31, 2022
The Annual Report and Long-Range Plan for Fiscal Year 2021-22 has been published. Click here for more information. Continue reading